VCYT — VERACYTE, INC.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1384101 ·
Last close
$49.15
Market Cap
$3.92B
52W High
$50.54
52W Low
$29.45
ADV30
1,253,866
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 139,071,000 | 101,159,000 | 22,646,000 | 28,707,000 | 1,436,400,000 | 263,136,000 | 91,994,000 |
| Dec 2025 | 140,636,000 | 101,973,000 | 39,908,000 | 41,149,000 | 1,406,019,000 | 362,578,000 | 96,443,000 |
| Sep 2025 | 131,872,000 | 91,282,000 | 23,112,000 | 19,137,000 | 1,367,787,000 | 315,573,000 | 110,120,000 |
| Jun 2025 | 130,164,000 | 89,769,000 | 14,312,000 | -980,000 | 1,344,104,000 | 219,499,000 | 123,047,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$136,307,000
Investing CF
$-9,209,000
Financing CF
$-4,222,000
CapEx
$-9,677,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.83
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-377,630,000
Inventory
$20,546,000
Receivables
$44,660,000
ST Investments
$50,311,000
EBIT TTM
$61,937,000
Pretax Income TTM
$68,201,000
Interest Exp TTM
$0
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$541,742,976
EBITDA
$104,212,000
Free Cash Flow
$104,506,000
Enterprise Value
$3,522,081,536
Total Cash
$439,060,000
Total Debt
$39,333,000
Shares Out
79,792,647
Trailing EPS
$1.08
Book Value
$16.50
ROE
6.9%
ROA
3.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 517,145,000 | 78,282,000 | 66,353,000 | 1,406,019,000 | 96,443,000 | — | 136,307,000 |
| Dec 2024 | 445,764,000 | 19,510,000 | 24,138,000 | 1,300,035,000 | 124,069,000 | — | 75,096,000 |
| Dec 2023 | 361,051,000 | -17,446,000 | -74,404,000 | 1,114,906,000 | 70,804,000 | — | 44,222,000 |
| Dec 2022 | 296,536,000 | -35,340,000 | -36,560,000 | 1,156,422,000 | 81,222,000 | — | 7,535,000 |
TTM Snapshot
Revenues TTM
$341,930,000
NetIncome TTM
$-37,315,000
OpCashFlow TTM
$0
Assets (Latest)
$1,300,035,000
Forward EPS
$1.90
Max Pain — expiry 2026-06-18
max pain strike: $45.00 · spot: $51.34 · call oi: 1,348 · put oi: 566
Expected Move to 2026-06-18:
±$6.00
(11.69%) —
implied range
$45.34 –
$57.34
· ATM straddle on $50.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CON | Concentra Group Holdings Parent, Inc. | $3.60B | $28.15 | — |
| CELC | Celcuity Inc. | $4.30B | $88.24 | — |
| BLLN | BillionToOne, Inc. | $4.31B | $103.95 | — |
| RDNT | RadNet, Inc. | $4.49B | $57.05 | — |
| OPCH | Option Care Health, Inc. | $3.33B | $21.23 | — |
News headlines (Yahoo Finance, 1h cache)
This Top Biotech Has Surged. CEO Explains Key To Veracyte's Success.
2026-06-16 12:00 · Yahoo
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
2026-06-10 12:30 · Yahoo
How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst Call
2026-06-04 17:08 · Yahoo
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
2026-06-04 15:30 · Yahoo
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
2026-06-01 11:30 · Yahoo
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
2026-05-30 12:00 · Yahoo
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
2026-05-29 19:15 · Yahoo
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
2026-05-27 15:07 · Yahoo
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
2026-05-25 15:19 · Yahoo
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago
2026-05-25 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.